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Intermittent, ambulatory dobutamine infusions in 
patients with severe congestive heart failure 
Thirteen ambulatory patients with severe congestive heart failure were treated with weekly, 
outpatient 48-hour infusions of dobutamine. All 13 patients had at least a 25% increase in 
cardiac output during initial dobutamine titration, with a corresponding improvement in systemic 
vascular resistance. improvement in functional class was achieved in only seven patients. 
Additionally, only three patients survived the 26-week study period. Although no change in 
ventricular ectopy was noted during the initial dobutamine infusions, six patients experienced 
sudden death; three other patients died of progressive heart failure and one died from pulmonary 
embolism. These data suggest that chronic intermittent ambulatory dobutamine infusions are 
only partly successful in improving symptoms and probably do not prolong survival in patients 
with severe congestive heart failure. Administration of this form of therapy on a clinical basis 
should be undertaken cautiously until safety and efficacy are demonstrated in prospective, 
controlled trials. (AM HEART J 1986;112:787.) 
Mark J. Krell, M.D., Eva M. Kline, R.N., Eric R. Bates, M.D., 
John McB. Hodgson, M.D., Lee R. Dilworth, M.D., Nathan Laufer, M.D., 
Robert A. Vogel, M.D., and Bertram Pitt, M.D. Ann Arbor, Mich. 
Dobutamine hydrochloride is an effective parenteral 
inotropic agent for the acute treatment of congestive 
heart failure.‘-” Although tachyphylaxis has been 
shown to occur with prolonged infusions,“, 7 sus- 
tained improvement in functional class, left ventric- 
ular function, and exercise tolerance has been dem- 
onstrated after 72-hour infusions.8-1’ Intermittent, 
outpatient therapy with dobutamine has recently 
been suggested for long-term inotropic support.1”,13 
In this study, 13 patients with severe congestive 
heart failure were treated with intermittent ambula- 
tory outpatient 48-hour dobutamine infusions and 
were then followed for up to 6 months. 
METHODS 
Patients. Thirteen ambulatory patients, mean age 62 2 
11 years, with New York Heart Association class III or IV 
heart failure, were studied. Their clinical characteristics 
are summarized in Table I. Patients were excluded if they 
had surgically correctable heart disease, myocardial 
infarction within 3 months, an associated terminal or 
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incapacitating medical illness, exercise-induced angina 
pectoris, or ventricular tachycardia (>:3 beats) on a 
24-hour continuous ECG recording. This study was 
approved by the institutional committees on human 
research. Informed consent was obtained from each 
patient. 
Study protocol. Patients were hospit,alized and stabi- 
lized on standard medical therapy. Radionuclide ventricu- 
lography was then performed with a conventional gamma 
camera (General Electric Data, Milwaukee, Wise.) 
equipped with an all-purpose high sensitivity, low-energy, 
parallel-hole collimator interfaced to a portable cardiac 
imaging computer (Medical Data Systems, Ann Arbor, 
Mich.). Acquisitions were performed in the lo-degree 
right anterior oblique, 45-degree left anterior oblique, and 
left lateral projections. Global left. ventricular ejection 
fraction was calculated using a variable region-of-interest 
software program. 
Patients then underwent right heart catheterization 
with a No. 7F triple-lumen pulmonary artery thermodilu- 
tion catheter (American Edwards Corp., Santa Ana, 
Calif.). After a SO-minute stabilization period, heart rate, 
blood pressure, pulmonary wedge pressure, and cardiac 
output were measured. Dobutamine infusion was then 
begun at 2.5 pg/kg/min. The dose was increased to 5.0,7.5, 
10.0, and 15.0 pg/kg/min at 20-minute intervals. Hemody- 
namic measurements were repeated at each stage. 
Afterwards, a subcutaneous infusion port system (Me- 
diPort, Cormed Inc., Medina, N.Y.) was implanted in the 
subclavicular fossa. The tip of the catheter attached to the 
port was inserted via the cephalic or subc*lavian vein to the 
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Table I. Clinical characteristics of 13 patients with chronic congestive heart failure 
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Abbreviations: Al = aldactone; Am = amiodarone; C = captopril; D = digoxin; F = furosemide; H = hydralazine; M = metolazone; N = nitrates; 
NYHA = New York Heart Association; Q = quinidine. 
Table II. Baseline hemodynamic data 
HR MAP PWP CI SVR LVEF - 
Patient no. (bpm) (mm Hd (mm Hd (Llmlm3 (dynes s cm-‘) (7,) 
1 89 84 31 1.6 1920 15 
2 78 92 20 1.5 2114 22 
3 76 85 15 1.8 1741 11 
4 80 87 18 1.8 1913 14 
5 a4 94 14 2.3 1780 16 
6 88 76 36 1.7 2133 18 
7 100 90 24 1.5 1694 15 
8 66 75 18 1.2 2588 22 
9 96 77 20 1.5 2529 14 
10 93 53 26 1.8 752 27 
11 105 79 31 1.4 1675 15 
12 82 90 38 1.7 1882 17 
13 70 82 26 1.4 2304 10 
Abbreviations: CI = cardiac index; HR = heart rate; LVEF = left ventricular ejection fraction; MAP = mean arterial pressure; PWP = pulmonary wedge 
pressure; SVR = systemic vascular resistance. 
junction of the right atrium and the superior vena cava. 
The dobutamine dose that gave the maximum cardiac 
output without inducing significant ventricular ectopy, a 
10 mm Hg rise in systolic blood pressure, a 10 bpm rise in 
heart rate, or other side effects was chosen for intermit- 
tent chronic infusion. 
Long-term follow-up. After hospital discharge, patients 
received weekly, 48-hour infusions of dobutamine hydro- 
chloride diluted to a total volume of 60 cc in normal saline. 
Solutions were infused via a right-angle Huber needle 
connected to an infusion pump (Cormed Inc., Medina, 
N.Y.) by standard extension tubing. Patients returned to 
the chronic twice weekly to have their infusions initiated 
and discontinued. After discontinuing the infusion, the 
port was flushed once with 5 cc of heparinized saline. 
Further care was not required until the next infusion. No 
change in concurrent medications occurred during the 
study period. 
Statistical analysis. Dobutamine titration hemody- 
namic data are given as mean + standard deviation. The 
paired t test was used to compare each dose with the zero 
dose, with an exeriment-wise alpha error of 5% using the 
Bonferroni multiple comparison method. A p value <O.Ol 
was considered significant. 
RESULTS 
Acute hemodynamic data. Baseline hemodynamic 
data before dobutamine titration are detailed in 
Table II. The individual hemodynamic responses to 
a 10 bg/kg/min infusion of dobutamine are depicted 
in Fig. 1. The mean acute hemodynamic responses to 
dobutamine titration are summarized in Table III. 
Although the trend was for increasing dobutamine 
infusion rates to increase heart rate and mean 
arterial pressure and to decrease pulmonary wedge 
pressure, the changes were statistically insignificant. 
Significant improvements in cardiac index and sys- 
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Fig. 1. Acute hemodynamic effects following dobutamine titration from baseline to 10 &kg/min. 
CZ = cardiac index; HR = heart rate; MAP = mean arterial pressure: PWP = pulmonary wedge pressure; 
SVR = systemic vascular resistance. 
Table III. Hemodynamic response to dobutamine titration 
--- -. _____ - ..~ 
Infusion rate HR MAP PWP 
I~gglkglmid No. Ibpm) (mm Hd (mm Hg) 
0 13 85 k 12 82 k 11 “4 f 8 1.6 ‘c .:i i 9% ” .463 
2.5 10 82 + 8 84 2 7 PO ? 9 2.1 f .4’ i s:i i- :w* 
5.0 12 85 t 11 83 -i- 7 ‘2 +_ 9 2.4 2 .tit 1 :i:i 1 :i- ‘41 ,yt 
7.5 9 86 i 10 83 + 6 24 i- 8 2.5 _t .6* : I1Xl _f 299’ 
10.0 13 87 t 10 84 +_ 8 20 f 9 2.7 ? .6t : :! I.$ + :w$t 
15.0 10 92 k 13 84 k 9 19 i 8 3.2 i .6t 0.56 .+ ‘217-t 
---__-__ 
Values arr mean t SD. 
Abbreviati<ms: (‘I = cardiac index; HR = heart rate: MAP = mean arterial p~rs~urr; PM’I’ = pulmonary wedge prrwm~: S,\ ,i := <vsirmir vahv!ili+r 
resistance. 
*p, < O.l)l vs. baseline. 
tD < 0.001 vs baseline 
temic vascular resistance were found at infusion 
rates ~2.5 pg/kg/min. All patients achieved at least 
a 25% increase in cardiac output on the dose that 
was subsequently chosen for the chronic infusion 
rate. This dose averaged 7.5 r*g/kg/min for the 
group. 
Follow-up and mortality (Table IV). Symptomatic 
improvement was achieved in 7 of 13 (54% ) 
patients. Four improved by one functional class, two 
improved by two classes, and one improved by three 
classes. Nevertheless, only three patients (Nos. 3, 5, 
and 13) survived the 26-week study period. Two of 
the surviving patients were the only patients in the 
group treated with amiodarone. Sudden death 
occurred in six patients, three died of progressive 
heart failure, and one died from pulmonary embo- 
lism. Three of the deaths occurred during the weekly 
48-hour infusion period: one patient died suddenly, 
while two died in cardiogenic shock. 
Table IV. Functional status and survival data 
Week Wwk Wrc’k Week 
Baseline 1 :; ::j 26 
---_-._ .-- -- --.- 
NYHA class 
I !) 0 0 I 2 
II 0 0 ;i 2 1 
III 4 5 ;: 1 0 
IV 9 8 4 0 
Dead (I 0 ;i x 10 
-- 
Abbwviatim: YYHA = New York Heart :1w&~tis :L. 
DISCUSSION 
Standard pharmacologic treatment of chronic 
congestive heart failure includes diuretics, digitalis, 
and vasodilator agents. While new oral inotropic 
agents remain investigational and unavailable to 
most patients,14-l6 encouraging reports on the use of 
single 72-hours-” or weekly outpatient infusionrP lzi 
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of dobutamine to provide chronic inotropic support 
in heart failure patients prompted us to pursue this 
mode of therapy in our patients. However, the 
results of the present study show that although 13 of 
13 (100%) patients had initial hemodynamic 
improvement and 7 of 13 (54%) patients had symp- 
tomatic improvement, eight (62%) died within 3 
months of starting therapy and 10 of 13 (77 % ) were 
dead after 6 months. 
One explanation for the more negative results in 
the present study than in those previously reported 
is that our patients were more hemodynamically 
compromised (mean ejection fraction 16%) mean 
cardiac index 1.6 L/min/m2, mean pulmonary artery 
wedge pressure 24 mm Hg, mean systemic vascular 
resistance 1925 dynes . s . cmm5) and thus had more 
severe heart failure and a worse prognosis. Patients 
in Unverferth’s series9 had a mean ejection fraction 
of 25% and a mean cardiac index of 2.0 L/mm/m? 8 
of 37 (22%) patients were dead at 10 weeks, though 
17 of 30 (57%) patients were dead at 10 months. 
Only 2 of 17 (12 % ) patients reported by Leier et all2 
were dead at 6 months, but their baseline cardiac 
index was 2.5 L/min/m2. Applefeld et a1.13 success- 
fully treated two patients for 6 months in a protocol 
similar to ours, but baseline cardiac indexes were 2.3 
and 2.7 L/min/m2, and baseline pulmonary artery 
wedge pressures were only 8 and 13 mm Hg. Support 
for the suggestion that the high mortality in our 
patients was due to the fact that they had more 
severe disease than did patients in previous studies 
of dobutamine therapy exists in the work by Maskin 
et a1.17 They did not find an improvement in exercise 
tolerance in their patients treated with dobutamine, 
as did Liang et al.” and Leier et a1.12 Mean baseline 
cardiac index, as in our patients, was 1.6 L/min/m*. 
Similarly, Weber et al.18 have experienced a 70% 
mortality over 3 to 5 months in patients with severe 
heart failure referred to them for investigational 
inotropic drug therapy. Finally, it should be noted 
that two of the three survivors in the present study 
had the lowest pulmonary wedge pressures in the 
group. 
Another possible explanation for the early mortal- 
ity in our patients is that dobutamine contributed to 
the six sudden deaths by precipitating malignant 
ventricular arrhythmias. Although increased ven- 
tricular ectopy is a recognized complication of acute 
inotropic drug infusions,1g*20 no change in ventricular 
ectopy was noted during the initial dobutamine 
infusions in this study. Of interest in this regard is 
the fact that two of our three survivors were being 
treated with amiodarone. None of the patients who 
died received amiodarone therapy. While the role of 
October, 1986 
American Heart Journal 
antiarrhythmic therapy in reducing mortality in 
patients with severe heart failure is uncertain, it 
should be pointed out that sudden death is relatively 
frequent in these patients and that digitalis, or other 
newer inotropic agents, may increase myocardial 
oxygen demands and hence predispose to ventricu- 
lar arrhythmias and sudden death. The relatively 
high mortality and incidence of sudden death 
reported with inotropic agents such as milrinone in 
patients with severe heart failure raises the possibil- 
ity that to be effective, these agents will have to be 
administered in conjunction with antiarrhythmic 
therapy. 
In conclusion, our data suggest that chronic inter- 
mittent ambulatory dobutamine infusions are only 
partly successful in improving symptoms and proba- 
bly do not prolong survival in patients with severe 
congestive heart failure. Administration of this form 
of therapy on a clinical basis should be undertaken 
cautiously until safety and efficacy are demon- 
strated in prospective, controlled trials. Whether 
additional interventions, such as amiodarone thera- 
py, or earlier intervention with intermittent dobu- 
tamine infusions or other inotropic agents before 
end-stage heart failure develops, can benefit 
patients with severe heart failure remains to be 
determined. 
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The hemodynamic determinants of the 
isovolumic index 
The isovolumic index is a recently described echocardiographic parameter of left ventricular 
function that is calculated as the ratio between the sum of the time of isovolumic contraction and 
relaxation divided by the ejection time. Although the individual components of this index may be 
altered by heart rate and loading conditions, an analysis of the net effect of such alterations on 
the isovolumic index has not been undertaken. Thus, dogs were instrumented with hlgh-fidelity 
micromanometers in the left ventricle, ascending aorta, and left atrium to allow determination of 
the individual components of the isovolumic index and calculation of the index itself. Four sets of 
experiments were undertaken in random order. Left atrial pacing was used to increase heart rate 
by approximately 10 bpm in five steps. Preload was elevated in five stages by saline infusions 
which caused successive increases of 1 to 2 mm Hg in the left ventricular end-diastolic pressure. 
Systolic blood pressure was lowered or raised by approximately 10 mm Hg per stage by three 
progressive, steady-state infusions of nitroprusside and phenylephrine, respectively. These 
experiments demonstrated little change in the isovolumic index over a broad range of heart rate. 
Increased left ventricular end-diastolic pressure and decreased systemic pressure caused 
shortening of the index. Multiple regression analysis of all experiments yielded the following: 
isovolumic index = 0.41 - 0.015 (left ventricular end-diastolic pressure) + 0.004 (systolic blood 
pressure); r = 0.57, standard error = 0.13, p < 0.0001. Therefore, this investigation establishes 
the hemodynamic determinants of the isovolumic index and provides the basis for Interpretation 
of directional changes in response to cardiac diseases and cardioactive drugs that can alter 
loading conditions. (AM HEART J 1986;112:791.) 
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